The US Food and Drug Administration (FDA) has issued a formal authorization for the use of emergency medication to treat “REMDIVIVIR” antiviral drugs for the treatment of suspected or clinically confirmed COVID-19 patients in adults and children in hospitals with severe illness.
The Food and Drug Administration emergency statement for remdesivir, which came two days after the clinical experience of the National Institutes of Health promising results, is an important step forward in the fight against the Corona virus.
FDA approval for the drug Reimserv
Permission to use in emergency situations allows the distribution of remdesivir to treat suspected or confirmed laboratory corona patients in adults and children in hospitals with severe disease, and severe disease is defined as patients with low levels of oxygen in the blood or need oxygen therapy or breathing support More intense like a ventilator.
The text of the FDA statement reads on its official website: “Based on the evaluation of emergency use licensing standards and available scientific evidence, it has been determined that it is reasonable to believe that Remdesivir may be effective in treating COVID-19, and that, as there are no appropriate, approved, or available alternative therapies available, Known and potential benefits of treating this dangerous or life-threatening virus Currently known and potential risks of drug use.
Emphasizing that important information on the use of remdesivir in the treatment of COVID-19 is available to healthcare providers and patients, including dosage instructions, possible side effects and drug interactions. Possible side effects of remedivir include: Increased levels of liver enzymes, which may be a sign of inflammation or damage to liver cells. And leak-related reactions, which may include low blood pressure, nausea, vomiting, sweating and tremors.
The FDA previously allowed study of the investigative drug under clinical trials, as well as extended use for individual patients and through a multi-patient expanded access program coordinated by Gilead Corporation.